Consistent and accurate measurement of retinoblastoma tumors is of important clinical value for treatment management. This paper presents an algorithm for the determination of retinoblastoma (RB) tumor to assist in the determination of tumor volume changes throughout treatment periods. The result of the development of a neural network approach for the analysis of three-dimensional ultrasound images shows that it is possible to identify retinoblastoma tumors and accurately determine the front and back boundary of the tumor. The algorithm used was a soft competitive learning network with two inputs. The outputs of the network identify the eye, the tumor, and the back of the eye.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/s0895-6111(00)00076-8 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Exploring the antiproliferative effect of PI3K/Akt/mTOR pathway and CDK4/6 inhibitors in human papillomavirus‑positive and ‑negative head and neck squamous cell carcinoma cell lines.
Int J Oncol
February 2025
Department of Pathology, GROW Research Institute for Oncology and Reproduction, Maastricht University Medical Center, 6229HX Maastricht, The Netherlands.
Human papillomavirus (HPV)‑positive and -negative head and neck squamous cell carcinoma (HNSCC) are often associated with activation of the phosphatidylinositol 3‑kinase (PI3K)/Akt/mammalian target of rapamycin (mTOR) pathway due to mutations or amplifications in , loss of or activation of receptor tyrosine kinases. In HPV‑negative tumors, (encoding p16 protein) inactivation or (encoding Cyclin D1 protein) amplification frequently results in sustained cyclin‑dependent kinase (CDK) 4/6 activation. The present study aimed to investigate the efficacy of the CDK4/6 inhibitors (CDKi) palbociclib and ribociclib, and the PI3K/Akt/mTOR pathway inhibitors (PI3Ki) gedatolisib, buparlisib and alpelisib, in suppressing cell viability of HPV‑positive and ‑negative HNSCC cell lines.
View Article and Find Full Text PDFRisk Factors for Extraocular Relapse in Retinoblastoma.
Semin Ophthalmol
January 2025
SJD Pediatric Cancer Center Barcelona, Hospital Sant Joan de Deu, Barcelona, Spain.
Background: Metastatic retinoblastoma remains a significant challenge in pediatric oncology, with stark disparities in survival outcomes between high-income countries (HICs) and low-income countries (LICs). Delayed diagnosis and treatment, driven by socioeconomic factors and limitations in healthcare systems, contribute to poorer outcomes in LICs. Histopathological characteristics, including high-risk pathology factors (HRPFs) and the extent of ocular tumor invasion, are critical for predicting metastatic risk and guiding treatment strategies.
View Article and Find Full Text PDFA retrospective study on ruthenium-106 and strontium-90 eye-plaques treatment for retinoblastoma: 16-years clinical experience.
Brachytherapy
January 2025
Ocular Oncology and Radiology Department, S. Fyodorov Eye Microsurgery Federal State Institution, Moscow, Russia.
Purpose: To retrospectively evaluate the efficacy of plaque brachytherapy for the treatment of retinoblastoma.
Methods: We retrospectively reviewed the clinical records of 163 patients (186 eyes, 333 tumors) treated with brachytherapy (Ru or Sr plaques) for intraocular retinoblastoma between November 2007 and August 2023.
Results: Complete tumor control was achieved in 273 tumors (82%).
Response to 'Critical appraisal of Gelfoam embolization technique in retinoblastoma treatment: a call for caution and further investigation'.
J Neurointerv Surg
January 2025
Department of Diagnostic and Interventional Radiology, CHUV - Lausanne University Hospital, Lausanne, Switzerland.
Mosaicism and intronic variants in RB1 gene revealed by next generation sequencing in a cohort of Spanish retinoblastoma patients.
Exp Eye Res
January 2025
Genetic Diagnosis Unit, Institute for Rare Diseases Research (IIER), Carlos III Institute of Health (ISCIII), Madrid, Spain; Center for Biomedical Research on Rare Diseases Network, Carlos III Institute of Health (ISCIII), Madrid, Spain (U758; CB06/07/1009; CIBERER-ISCIII).
Constitutional variants in the RB1 gene predispose individuals to the development of Retinoblastoma (RB) and the occurrence of second tumors in adulthood. Detection of causal RB1 gene variants is essential to establish the genetic diagnosis and to performing familial studies and counseling. In our cohort of 579 Spanish RB patients, 15% of cases suspected to have a genetic origin remained negative after traditional Sanger sequencing and Multiplex Ligation-dependent Probe Amplification (MLPA) of RB1 gene, likely due to the possibility of mosaicism or non-coding variants.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!